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The prevalence of congenital myopathies in the United
States has not been examined. To address this, we
determined the point prevalence of congenital myopa-
thies in a well-defined pediatric population from South-
eastern Michigan. The overall point prevalence was
1:26,000. Mutations in RYR1 were the most common
cause of congenital myopathies at 1:90,000. Our data
broadly agrees with estimates from previous European
studies and provides the first estimate of the prevalence
of congenital myopathies in the United States.
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Congenital myopathies are a heterogeneous group ofneuromuscular disorders that typically present in
childhood.1 They are largely defined by clinical presenta-
tion and characteristic features on biopsy. While preva-
lence data from multiple different countries exists for
Duchenne muscular dystrophy and spinal muscular atro-
phy,2 much less is known about the epidemiology of
congenital myopathies. Historically, this group of condi-
tions is considered to be quite rare, though no single
study has exclusively and systematically examined them.
Three previous studies provided estimates of the
prevalence of these disorders. One study examined a
cohort from Northern Ireland and estimated the preva-
lence of congenital myopathies (adult and pediatric) as
1:28,600.3 A retrospective epidemiologic study of pediat-
ric neuromuscular cases performed for western Sweden
determined the prevalence of congenital myopathies as
1:22,480.4 Additionally, they found that the most preva-
lent specific subtype was nemaline myopathy
(1:179,000), though unspecified congenital myopathies
were significantly more common (1:27,000). Most
recently, the prevalence of neuromuscular disorders was
examined in a cohort from northern England.5 In this
study, the prevalence of congenital myopathies (adult and
pediatric) was 1:135,000, with central core disease the
most prevalent at 1:249,000.
Currently, no estimates exist concerning the preva-
lence of congenital myopathies in the United States. Bar-
riers to defining such data are the following: (1) the large
size of the U.S. population; (2) the lack of centralization
of neuromuscular centers; and (3) the lack of accessible
records for epidemiologic studies. One approach for
overcoming these problems is to examine a well-defined
subset of the population. In the current study, we have
taken such an approach by performing an epidemiologic
analysis of the prevalence of congenital myopathies in the
pediatric population of southeastern Michigan. This pop-
ulation is large (approximately 1.2 million aged 0–17
years), has demographics similar to the overall U.S. pop-
ulation, and is serviced by a defined number of pediatric
neuromuscular clinics.6
We present the prevalence data from our epidemio-
logic study. We found that the overall point prevalence
in 2010 of confirmed pediatric cases of congenital myop-
athies is 1:26,000. The largest subgroup was the unspeci-
fied group (prevalence ¼ 1:55,000), whereas the most
common specific histopathologic subtype was the core
myopathies (1:80,000). In all, our study provides the first
estimate of the frequency of congenital myopathies in a
pediatric population in the United States and provides a




The population of the state of Michigan is divided into well-
defined geopolitical regions. The largest region in the state is
the Ann Arbor–Detroit–Flint area in southeastern Michigan
(Fig 1). According to the last systematic examination of this
area by the U.S. Census bureau in 2007,6 the population of
individuals under the age of 18 years is 1,211,100. The demo-
graphics for this group are 75% white, 22% black or African-
American, and 3% Latino. The overall demographics for the
United States population are 80% white, 13% black or African-
American, and 16% Latino.6
Ascertainment
We hypothesized that all, or nearly all, pediatric patients with
congenital myopathies receive clinical care in a Muscular Dystro-
phy Association (MDA) sponsored clinic. Currently, there are 3
MDA clinics in the Ann Arbor–Detroit–Flint area that provide
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clinical services for children. We collected clinical and diagnostic
data on patients from these clinics using a retrospective chart
review. Duplicate cases were excluded by using individual identi-
fying information. Chart reviews were performed over a 3-month
period between September 2010 and December 2010.
Inclusion Criteria
Inclusion criteria for the study were as follows: (1) age under 18
years (as of December 2010), (2) alive in 2010, (3) residence in
Michigan, (4) evaluation in 1 of the 3 MDA clinics between Jan-
uary 2005 and December 2010, and (5) a confirmed diagnosis of
congenital myopathy. The diagnosis of congenital myopathy was
based on a consistent clinical history and at least 1 additional sup-
porting study (biopsy, genetic testing, or first-degree relative).
The subtypes included in this study were centronuclear myopa-
thy, central core disease, multiminicore disease, nemaline myopa-
thy, and congenital fiber type disproportion. Nonspecific biopsies
were defined as those containing myopathic features without evi-
dence of a defined histopathological subtype.
Exclusion Criteria
Cases with a clinical diagnosis of congenital myopathy without
supporting confirmatory data were not included in the preva-
lence totals. In addition, patients with a concomitant diagnosis
(such as Down syndrome, other neuromuscular disease, etc.)
were also excluded from the study.
Institutional Review Boards
This study was reviewed by the Institutional Review Boards
(IRBs) at the University of Michigan and at Wayne State Uni-




A total of 62 patients were identified with a clinical diag-
nosis of congenital myopathy. Of these patients, 46 had
diagnostic testing (41) or family history (5) consistent
with a congenital myopathy and thus were included in
the point prevalence calculation. Using a population esti-
mate for southeastern Michigan of 1,211,100, the overall
point prevalence for pediatric congenital myopathies in
this region is 1:26,000 (Fig 2).
Subtype Prevalence
HISTOPATHOLOGIC SUBTYPE. Congenital myopa-
thies are most commonly defined by biopsy pattern. In
our cohort, the most common specific histologic sub-
types are minicore myopathy and central core disease,
representing 8 of 44 and 7 of 44 biopsies, respectively.
The largest proportion of cases (22/44) is represented by
those with a nonspecific biopsy pattern. Of these cases,
10 biopsies showed type I fiber predominance and 15
showed fiber atrophy/hypertrophy. The prevalence data
for all subtypes is presented in the Table.
GENETIC SUBTYPE. A causative genetic mutation was
identified in 16 of 46 cases. Thirteen patients had RYR1
mutations. The prevalence of myopathies due to muta-
tions in RYR1 (including 2 cases in which the sibling or
parent had a positive gene test) is 1:90,000. Other causes
of congenital myopathies and other related disorders
were ruled out in several patients through genetic testing
FIGURE 1: The lower peninsula of the state of Michigan
(adapted from the Michigan Business Directory). The Ann
Arbor–Flint–Detroit catchment area is outlined by a black
line. The estimated pediatric population in this area is
1,200,000.
FIGURE 2: Breakdown by percentage of each congenital
myopathy subtype based on biopsy findings. CCD 5 central
core disease; CFTD 5 congenital fiber-type disproportion;
CNM 5 centronuclear myopathy; MmD 5 multiminicore
disease.
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including: myotonic dystrophy (13/46), RYR1 (4/46),
SEPN1 (4/46), LMNA (2/46), ACTA1 (1/46), TPM2 (1/
46), TPM3 (1/46), DNM2 (1/46), MTM1 (1/46),
COL6A1-3 (3/46), SMN1 (4/46), PYGM (1/46), PFKM
(1/46), deletion of 4q35 (FSHD) (2/46), and enzymatic
testing for Pompe disease (1/46).
Dystrophinopathy Prevalence
As an internal control, we collected the number of dys-
trophinopathy patients. We identified 169 male patients
with genetically confirmed dystrophinopathy with a prev-
alence of 1:7,000.
Discussion
We present for the first time the prevalence of congenital
myopathies in a representative pediatric United States
population. By examining a defined population from
Southeastern Michigan, we determined a prevalence of
1:26,000. We predict that this number accurately reflects
the overall pediatric prevalence of congenital myopathies
in the United States. This is for 3 reasons: (1) the demo-
graphics of our cohort is similar to that of the general
U.S. population, (2) our ascertainment ‘‘control’’ cohort
(ie, dystrophinopathy patients) revealed a number
(1:3,500 boys) in keeping with known calculations7 and
thus indicative of complete or near complete ascertain-
ment in our defined population, and (3) our prevalence
number shows excellent agreement with those calculated
in previous European studies (1:22,000 in Sweden and
1:28,000 in Northern Ireland). The exception was the
recent study from Northern England, which determined
prevalence as 1:135,000. This discrepancy is likely the
result of the fact that this estimate did not include cases
of nonspecific congenital myopathies.
Of note, given that our study was confined to a
pediatric population, our estimate likely is an underrepre-
sentation of the overall prevalence of congenital myopa-
thies in the United States. It does not account for cases
with adult onset or cases with mild pediatric onset that
are not diagnosed until adulthood. However, as the ma-
jority of patients with congenital myopathies have onset
and diagnosis in childhood, we hypothesize that our
number represents a good estimate of the overall burden
of these disorders. The fact that our prevalence number
is very similar to the previous European studies (which
included all ages) supports this conclusion.
Two additional significant findings are that core
myopathies are the most common specific histopatho-
logic subtype, and that congenital myopathies due to
mutations in RYR1 are by the far the most prevalent
genetic subtype in our population. This is in keeping
with the recent explosion in the medical literature of
reports of RYR1 mutations in essentially all histologic
subtypes of congenital myopathies.8–10 This finding is
also consistent with the data from northern England, but
is at odds with the study from Sweden. In the Swedish
cohort, nemaline myopathy was the most common sub-
type. This may reflect ethnic and geographic variability
in terms of subtype distribution, as we uncovered only a
single case of nemaline in our population.
The largest subgroup within our cohort was the
‘‘nonspecific’’ group. Patients in this group had a suggestive
clinical history and a biopsy with nonspecific myopathic
features. This was also the largest group in the Swedish
study. It is unclear whether this group represents cases that
will ultimately have a specific diagnosis, will continue to
remain undefined, or will instead be recognized as having
a different muscle condition that does not fall in the con-
genital myopathy spectrum. The fact that so many cases
are undefined underscores the important point that muscle
biopsy is often not sufficiently diagnostic. Additional and
potentially novel modalities are thus needed in many cases
to establish the ultimate diagnosis.
In all, we have established for the first time the
prevalence of congenital myopathies in a representative
U.S. subpopulation. We have also identified RYR1 muta-
tions as the commonest genetic cause of congenital my-
opathies. We thus recommend a high degree of suspicion
for RYR1 mutations in all genetically undefined cases of
congenital myopathy.










CNM 3 1 1:400,000
Core
myopathies
CCD 7 5 1:170,000
MmD 8 3 1:150,000
Nemaline 1 1 1:1,210,000
CFTD 5 1 1:240,000
Total 62 16 1:26,000
CCD ¼ central core disease; CFTD ¼ congenital fiber-type
disproportion; CNM ¼ centronuclear myopathy; MmD ¼
multiminicore disease; N/A ¼ not applicable.
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